These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
763 related articles for article (PubMed ID: 23929302)
1. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302 [TBL] [Abstract][Full Text] [Related]
2. Galectin-1 and immunotherapy for brain cancer. Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926 [TBL] [Abstract][Full Text] [Related]
3. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Pellegatta S; Poliani PL; Stucchi E; Corno D; Colombo CA; Orzan F; Ravanini M; Finocchiaro G Neuro Oncol; 2010 Apr; 12(4):377-88. PubMed ID: 20308315 [TBL] [Abstract][Full Text] [Related]
4. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203 [TBL] [Abstract][Full Text] [Related]
5. Basic concepts in glioma immunology. Parney IF Adv Exp Med Biol; 2012; 746():42-52. PubMed ID: 22639158 [TBL] [Abstract][Full Text] [Related]
6. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997 [TBL] [Abstract][Full Text] [Related]
7. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977 [TBL] [Abstract][Full Text] [Related]
8. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Baker GJ; Chockley P; Yadav VN; Doherty R; Ritt M; Sivaramakrishnan S; Castro MG; Lowenstein PR Cancer Res; 2014 Sep; 74(18):5079-90. PubMed ID: 25038230 [TBL] [Abstract][Full Text] [Related]
9. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019 [TBL] [Abstract][Full Text] [Related]
10. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886 [TBL] [Abstract][Full Text] [Related]
11. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066 [TBL] [Abstract][Full Text] [Related]
12. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. Dey M; Chang AL; Miska J; Wainwright DA; Ahmed AU; Balyasnikova IV; Pytel P; Han Y; Tobias A; Zhang L; Qiao J; Lesniak MS J Immunol; 2015 Jul; 195(1):367-76. PubMed ID: 26026061 [TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916 [TBL] [Abstract][Full Text] [Related]
14. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. Kuo PL; Hung JY; Huang SK; Chou SH; Cheng DE; Jong YJ; Hung CH; Yang CJ; Tsai YM; Hsu YL; Huang MS J Immunol; 2011 Feb; 186(3):1521-30. PubMed ID: 21191065 [TBL] [Abstract][Full Text] [Related]
15. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Garg AD; Vandenberk L; Koks C; Verschuere T; Boon L; Van Gool SW; Agostinis P Sci Transl Med; 2016 Mar; 8(328):328ra27. PubMed ID: 26936504 [TBL] [Abstract][Full Text] [Related]
17. Microenvironment involved in FPR1 expression by human glioblastomas. Boer JC; van Marion DM; Joseph JV; Kliphuis NM; Timmer-Bosscha H; van Strijp JA; de Vries EG; den Dunnen WF; Kruyt FA; Walenkamp AM J Neurooncol; 2015 May; 123(1):53-63. PubMed ID: 25894595 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Morin-Brureau M; Hooper KM; Prosniak M; Sauma S; Harshyne LA; Andrews DW; Hooper DC Cancer Immunol Immunother; 2015 Apr; 64(4):447-57. PubMed ID: 25579379 [TBL] [Abstract][Full Text] [Related]